Iolyx Therapeutics Announces Promising Phase II Results for ILYX-002 in Autoimmune Dry Eye Disease
ILYX-002 shows 3x greater corneal healing effect compared to current therapies on the market. Iolyx Therapeutics (California, United States), a…
From Research to Reality: The Corneal Innovations at APAO 2025 Poised to Transform Ophthalmology
Breakthrough corneal technologies on display at APAO-AIOC 2025 could revolutionize corneal treatment amidst a worldwide donor shortage. Ophthalmic translational medicine…
latest posts
